Türkiye Pharma Reimbursement: 2026 Outlook
Navigating the pharmaceutical landscape in Türkiye requires more than just a great product; it requires a deep understanding of one of the world’s most unique and regulated reimbursement systems.
As of January 2026, the Turkish pharmaceutical market continues to be a complex environment where patient access, government fiscal goals, and international pricing standards intersect. For pharma companies and healthcare stakeholders, staying updated on these mechanisms is critical for a successful market entry strategy.
The Pillars of the Turkish Reimbursement System
Reimbursement in Türkiye is primarily managed by the Social Security Institution (SGK). With nearly 98% coverage of the population under a unified health insurance scheme, the SGK is effectively the “sole payer,” giving it immense bargaining power.
1. The Gateway: TİTCK and Licensing
Before a drug can even be considered for reimbursement, it must be licensed by the Turkish Medicines and Medical Devices Agency (TİTCK). This process follows international standards (CTD format) and requires a Good Manufacturing Practices (GMP) certificate.
2. The Price Tag: External Reference Pricing (ERP)
Türkiye uses a reference pricing system based on the lowest price among five EU countries: France, Italy, Spain, Portugal, and Greece.
-
The 2026 Update: In a major move to reflect economic shifts, the government increased the base Euro exchange rate for drug pricing to 25.3346 TRY (an approximate 17% increase from 2025). While this helps alleviate some supply pressure, it still sits significantly below the real-market exchange rate, maintaining a challenge for imported innovative medicines.
3. The “Positive List” (SUT)
To be reimbursed, a drug must be included in the Health Implementation Communiqué (SUT) lists. Applications are reviewed by the Medical and Economic Evaluation Committee (TEDK) and the Reimbursement Committee, focusing on:
-
Cost-effectiveness.
-
Budget impact analysis.
-
Clinical superiority compared to existing treatments.
Current Trends and Challenges in 2026
Alternative Reimbursement Models (ARM)
Since 2016, and with updated regulations in 2023–2025, Türkiye has leaned heavily into Alternative Reimbursement Agreements. These are confidential, “special” contracts between the SGK and pharma companies.
-
Why they matter: They allow for flexible pricing or “pay-back” schemes for innovative or high-cost drugs (like oncology or orphan drugs) that might not fit the rigid standard pricing rules.
-
Confidentiality: These agreements keep discount rates private, protecting the company’s global price floors while ensuring Turkish patients get access.
The Pricing Pressure & Mandatory Discounts
Standard reimbursement comes with mandatory “public institution discounts” (kamu kurum iskontosu). These can reach up to 41% for original drugs and 28% for generics. Combined with the fixed exchange rate, this creates a high-pressure environment for international manufacturers.
Patient Lawsuits for Non-Reimbursed Meds
A notable trend in recent years has been the rise of individual lawsuits by patients (particularly for advanced cancer therapies like Pembrolizumab or Nivolumab). Courts have frequently ruled in favor of patients, forcing the SGK to cover treatments not yet on the official reimbursement list, provided they are recommended by international guidelines.
Key Strategies for Success
If you are a pharma professional looking to navigate this market, consider these three pillars:
-
Early Engagement: Don’t wait for licensing to finish. Start the dialogue with the SGK regarding “Value-Based” or “Alternative” models early.
-
Robust HEOR Data: Health Economics and Outcomes Research (HEOR) is no longer optional. The SGK requires localized budget impact models that speak to the Turkish demographic specifically.
-
Local Production Incentives: The government heavily favors “localization.” Manufacturing locally can provide a significant “leg up” in the reimbursement queue and pricing negotiations.
Looking Ahead
The Turkish market remains a “high-volume, low-margin” environment. While the 2026 exchange rate update offers some breathing room, the focus remains on sustainability. Companies that can demonstrate long-term value and a commitment to the Turkish healthcare ecosystem will find the most success.